Histone deacetylase inhibitor valproic acid suppresses the growth and increases the androgen responsiveness of prostate cancer cells

Cancer Letters

Volumn 311, Issue 2, 2011, Pages 177-186

  Chou, Yu Wei ^a   Chaturvedi, Nagendra K ^a   Ouyang, Shougiang ^a   Lin, Fen Fen ^a   Kaushik, Dharam ^a,b   Wang, Jue ^a,b   Kim, Isaac ^c   Lin, Ming Fong ^a,b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Androgen responsiveness; CPAcP; ErbB 2; HDAC inhibitors; Prostate cancer

Indexed keywords

ACID PHOSPHATASE; ANDROGEN; CYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HISTONE H3; HISTONE H4; SHORT HAIRPIN RNA; VALPROIC ACID;

ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; HISTONE ACETYLATION; HISTONE METHYLATION; HORMONE RESPONSE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ANTINEOPLASTIC AGENTS; BLOTTING, NORTHERN; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SEPARATION; FLOW CYTOMETRY; HISTONE DEACETYLASE INHIBITORS; HUMANS; MALE; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROTEIN TYROSINE PHOSPHATASES; RECEPTOR, ERBB-2; VALPROIC ACID;

EID: 80053130009     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.07.015     Document Type: Article

References (52)

1. Jemal A., Siegel R., Ward E., Hao Y.P., Xu J.Q., Murray T., Thun M.J. Cancer statistics, 2008. CA. Cancer J. Clin. 2008, 58:71-96.
2. Abbas A., Gupta S. The role of histone deacetylases in prostate cancer. Epigenetics 2008, 3:300-309.
3. Herman J.G., Baylin S.B. Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med. 2003, 349:2042-2054.
4. Minucci S., Pelicci P.G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 2006, 6:38-51.
5. Waltregny D., North B., Van Mellaert F., de Leval J., Verdin E., Castronovo V. Screening of histone deacetylases (HDAC) expression in human prostate cancer reveals distinct class I HDAC profiles between epithelial and stromal cells. Eur. J. Histochem. 2004, 48:273-290.
6. Weichert W., Roske A., Gekeler V., Beckers T., Stephan C., Jung K., Fritzsche F.R., Niesporek S., Denkert C., Dietel M., Kristiansen G. Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br. J. Cancer 2008, 98:604-610.
7. R. Rodriguez, Sidney kimmel Comprehensive Cancer Center at Johns Hopkins, Valproic acid in Treating Patients with Progressive, Non-metastatic Prostate Cancer, National Cancer Institute NCT00670046, 2009.
8. Vihko P. Human prostatic acid phosphatases: purification of a minor enzyme and comparisons of the enzymes. Invest. Urol. 1979, 16:349-352.
9. Lad P.M., Cooper J.F., Learn D.B., Olson C.V. Identification of structural and secretory lectin-binding glycoproteins of normal and cancerous human prostate. Biochim. Biophys. Acta 1984, 791:186-197.
10. Veeramani S., Yuan T.C., Chen S.J., Lin F.F., Petersen J.E., Shaheduzzaman S., Srivastava S., MacDonald R.G., Lin M.F. Cellular prostatic acid phosphatase: a protein tyrosine phosphatase involved in androgen-independent proliferation of prostate cancer. Endocr. Relat. Cancer 2005, 12:805-822.
11. Huggins C., Hodges C.V. Studies on prostatic cancer: the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941, 1:293-297.
12. Chu T.M., Lin M.F. PSA and acid phosphatase in the diagnosis of prostate cancer. J. Clin. Ligand Assay 1998, 21:24-34.
13. Reif A.E., Schlesinger R.M., Fish C.A., Robinson C.M. Acid phosphatase isozymes in cancer of the prostate. Cancer 1973, 31:689-699.
14. Hakalahti L., Vihko P., Henttu P., Autio-Harmainen H., Soini Y., Viko R. Evaluation of PAP and PSA gene expression in prostatic hyperplasia and prostatic carcinoma using northern-blot analyses, in situ hybridization and immunohistochemical stainings with monoclonal and bispecific antibodies. Int. J. Cancer 1993, 55:590-597.
15. Lin M.F., Lee M.S., Zhou X.W., Andressen J.C., Meng T.C., L Johansson S., West W.W., Taylor R.J., Anderson J.R., Lin F.F. Decreased expression of cellular prostatic acid phosphatase increases tumorigenicity of human prostate cancer cells. J. Urol. 2001, 166:1943-1950.
16. Sakai H., Yogi Y., Minami Y., Yushita Y., Kanetake H., Saito Y. Prostate specific antigen and prostatic acid phosphatase immunoreactivity as prognostic indicators of advanced prostatic carcinoma. J. Urol. 1993, 149:1020-1023.
17. Sinha A.A., Gleason D.F., Wilson M.J., Wick M.R., Reddy P.K., Blackar C.E. Relationship of prostatic acid phosphatase localization in human prostate by a monoclonal antibody with the Gleason Grading System. Prostate 1988, 13:1-15.
18. Lin M.F., DaVolio J., Garcia-Arenas R. Expression of human prostatic acid phosphatase activity and the growth of prostate carcinoma cells. Cancer Res. 1992, 52:4600-4607.
19. Lin M.F., Garcia-Arenas R., Xia X.Z., Biela B., Lin F.F. The cellular level of prostatic acid phosphatase and the growth of human prostate carcinoma cells. Differentiation 1994, 57:143-149.
20. Lin M.F., Meng T.C., Rao P.S., Chang C., Schonthal A.H., Lin F.F. Expression of human prostatic acid phosphatase correlates with androgen-stimulated cell proliferation in prostate cancer cell lines. J. Biol. Chem. 1998, 273:5939-5947.
21. Lin M.F., Clinton G.M. Human prostatic acid phosphatase has phosphotyrosyl protein phosphatase activity. Biochem. J. 1986, 235:351-357.
22. Li H.C., Chernoff J., Chen L.B., Kirschonbaum A. A phosphotyrosyl-protein phosphatase activity associated with acid phosphatase from human prostate gland. Eur. J. Biochem. 1984, 138:45-51.
23. Lin M.F., Clinton G.M. The epidermal growth factor receptor from prostate cells is dephosphorylated by a prostate-specific phosphotyrosyl phosphatase. Mol. Cell Biol. 1988, 8:5477-5485.
24. Meng T.C., Lin M.F. Tyrosine phosphorylation of c-ErbB-2 is regulated by the cellular form of prostatic acid phosphatase in human prostate cancer cells. J. Biol. Chem. 1998, 273:22096-22104.
25. Zhang X.Q., Lee M.S., Zelivianski S., Lin M.F. Characterization of a prostate-specific tyrosine phosphatase by mutagenesis and expression in human prostate cancer cells. J. Biol. Chem. 2001, 276:2544-2550.
26. Igawa T., Lin F.F., Rao P., Lin M.F. Suppression of LNCaP prostate cancer xenograft tumors by a prostate-specific protein tyrosine phosphatase, prostatic acid phosphatase. Prostate 2003, 55:247-258.
27. Chuang T.D., Chen S.J., Lin F.F., Veeramani S., Kumar S., Batra S.K., Tu Y., Lin M.F. Human prostatic acid phosphatase, an authentic tyrosine phosphatase, dephosphorylates ErbB-2 and regulates prostate cancer cell growth. J. Biol. Chem. 2010, 285:23598-23606.
28. Meng T.C., Lee M.S., Lin M.F. Interaction between protein tyrosine phosphatase and protein tyrosine kinase is involved in androgen-promoted growth of human prostate cancer cells. Oncogene 2000, 19:2664-2677.
29. Zylka M.J., Sowa N.A., Taylor-Blake B., Twomey M.A., Herrala A., Voikar V., Vihko P. Prostatic acid phosphatase is an ectonucleotidase and suppresses pain by generating adenosine. Neuron 2008, 60:111-122.
30. Igawa T., Lin F.F., Lee M.S., Karan D., Batra S.K., Lin M.F. Establishment and characterization of androgen-independent human prostate cancer LNCaP cell model. Prostate 2002, 50:222-235.
31. Dillard P.R., Lin M.F., Khan S.A. Androgen-independent prostate cancer cells acquire the complete steroidogenic potential of synthesizing testosterone from cholesterol. Mol. Cell Endocrinol. 2008, 295:115-120.
32. Chen S.J., Karan D., Johansson S.L., Lin F.F., Zeckser J., Singh A.P., Batra S.K., Lin M.F. Prostate-derived factor as a paracrine and autocrine factor for the proliferation of androgen receptor-positive human prostate cancer cells. Prostate 2007, 67:557-571.
33. Thalmann G.N., Sikes R.A., Wu T.T., Degeorges A., Chang S.M., Ozen M., Pathak S., Chung L.W.K. LNCaP progression model of human prostate cancer: androgen-independence and osseous metastasis. Prostate 2000, 44:91-103.
34. Zelivianski S., Igawa T., Lim S., Taylor R., Lin M.F. Identification and characterization of regulatory elements of the human prostatic acid phosphatase promoter. Oncogene 2002, 21:3696-3705.
35. Veeramani S., Igawa T., Yuan T.C., Lin F.F., Lee M.S., Lin J.S., Johansson S.L., Lin M.F. Expression of p66(Shc) protein correlates with proliferation of human prostate cancer cells. Oncogene 2005, 24:7203-7212.
36. Zelivianski S., Larson C., Seberger J., Taylor R., Lin M.F. Expression of human prostatic acid phosphatase gene is regulated by upstream negative and positive elements. Biochim. Biophys. Acta 2000, 1491:123-132.
37. Kondo Y., Shen L., Cheng A.S., Ahmed S., Boumber Y., Charo C., Yamochi T., Urano T., Furukawa K., Kwabi-Addo B., Gold D.L., Sekido Y., Huang T.H., Issa J.P. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat. Genet. 2008, 40:741-750.
38. Wedel S.A., Sparatore A., Soldato P.D., Al-Batran S.E., Atmaca A., Juengel E., Hudak L., Jonas D., Blaheta R.A. New histone deacetylase inhibitors as potential therapeutic tools for advanced prostate carcinoma. J. Cell Mol. Med. 2008, 12:2457-2466.
39. Wu L.P., Wang X., Li L., Zhao Y., Lu S., Yu Y., Zhou W., Liu X., Yang J., Zheng Z., Zhang H., Feng J., Yang Y., Wang H., Zhu W.G. Histone deacetylase inhibitor depsipeptide activates silenced genes through decreasing both CpG and H3K9 methylation on the promoter. Mol. Cell Biol. 2008, 28:3219-3235.
40. Hunter T., Cooper J.A. Epidermal growth factor induces rapid tyrosine phosphorylation of proteins in A431 human tumor cells. Cell 1981, 24:741-752.
41. Lin M.F., Garcia-Arenas R. Effect of cell density on androgen regulation of the mRNA level of human prostatic acid phosphatase. Mol. Cell Endocrinol. 1994, 99:R21-24.
42. Pfeiffer D., Kimmig R., Herrmann J., Ruge M., Fisseler-Eckhoff A., Scheidel P., Jensen A., Schatz H., Pfeiffer A. Epidermal-growth-factor receptor correlates negatively with cell density in cervical squamous epithelium and is down-regulated in cancers of the human uterus. Int. J. Cancer 1998, 79:49-55.
43. Li L.C., Carroll P.R., Dahiya R. Epigenetic changes in prostate cancer: implication for diagnosis and treatment. J. Natl. Cancer Inst. 2005, 97:103-115.
44. Gottlicher M., Minucci S., Zhu P., Kramer O.H., Schimpf A., Giavara S., Sleeman J.P., Lo Coco F., Nervi C., Pelicci P.G., Heinzel T. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 2001, 20:6969-6978.
45. Xu W.S., Parmigiani R.B., Marks P.A. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007, 26:5541-5552.
46. Xia Q., Sung J., Chowdhury W., Chen C.L., Hoti N., Shabbeer S., Carducci M., Rodriguez R. Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo. Cancer Res. 2006, 66:7237-7244.
47. Iacopino F., Urbano R., Graziani G., Muzi A., Navarra P., Sica G. Valproic acid activity in androgen-sensitive and -insensitive human prostate cancer cells. Int. J. Oncol. 2008, 32:1293-1303.
48. Garcia-Arenas R., Lin F.F., Lin D., Jin L.P., Shih C.C., Chang C., Lin M.F. The expression of prostatic acid phosphatase is transcriptionally regulated in human prostate carcinoma cells. Mol. Cell Endocrinol. 1995, 111:29-37.
49. Campiglio M., Locatelli A., Olgiati C., Normanno N., Somenzi G., Viganò L., Fumagalli M., Ménard S., Gianni L. Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 ('Iressa') is independent of EGFR expression level. J. Cell Physiol. 2004, 198:259-268.
50. Sheng G., Guo J., Warner B.W. Epidermal growth factor receptor signaling modulates apoptosis via p38alpha MAPK-dependent activation of Bax in intestinal epithelial cells. Am. J. Physiol. Gastrointest. Liver Physiol. 2007, 293:599-606.
51. Hirsch C.L., Bonham K. Histone deacetylase inhibitors regulate p21WAF1 gene expression at the post-transcriptional level in HepG2 cells. FEBS Lett. 2004, 570:37-40.
52. Zhao Y., Lu S., Wu L., Chai G., Wang H., Chen Y., Sun J., Yu Y., Zhou W., Zheng Q., Wu M., Otterson G.A., Zhu W.G. Acetylation of p53 at lysine 373/382 by the histone deacetylase inhibitor depsipeptide induces expression of p21Waf1/Cip1. Mol. Cell Biol. 2006, 26:2782-2790.